Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.

The invention relates to mixtures of at least one diphosphinic acid of the formula (I)

##STR00001## in which R.sup.1, R.sup.2 are the same or different and are each independently H, C.sub.1-C.sub.18-alkyl, C.sub.2-C.sub.18-alkenyl, C.sub.6-C.sub.18-aryl, C.sub.7-C.sub.18-alkylaryl, R.sup.5 is C.sub.1-C.sub.18-alkylene, C.sub.2-C.sub.18-alkenylene, C.sub.6-C.sub.18-arylene, C.sub.7-C.sub.18-alkylarylene with at least one dialkylphosphinic acid of the formula (II)

##STR00002## in which R.sup.3, R.sup.4 are the same or different and are each independently C.sub.1-C.sub.18-alkyl, C.sub.2-C.sub.18-alkenyl, C.sub.6-C.sub.18-aryl and/or C.sub.7-C.sub.18-alkylaryl.

The invention also relates to a process for preparing these mixtures and to the use thereof.

The present provides a process for preparing dialkyl phosphinate, comprising: (1) firstly adding 0-99% of the total weight of phosphinic acids and/or salts thereof and a solvent into a reaction kettle; (2) in the reaction kettle in the presence of alkene and initiator, continuously adding 1-100% of the total weight of the phosphinic acids and/or salts thereof into the reaction system, during the addition process, when the mole contents of monoalkyl phosphinic acids and/or salts thereof account for 10% or less of the total molar contents of phosphorus in the reaction system, stopping adding the phosphinic acids and/or salts thereof. Also providing a dialkyl phosphinate flame retardant prepared by above preparation process.

There are provided compounds of formula I, ##STR00001##
wherein R.sup.1 to R.sup.5, X.sup.1, X.sup.2, Ar, L, A, A.sup.1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Provided are a near-infrared-ray-absorbing composition having strong near-infrared shielding properties when a cured film is produced, a near-infrared-ray cut filter, a manufacturing method therefor, a camera module, and a manufacturing method therefor. The near-infrared-ray-absorbing composition includes a copper complex obtained by reacting a compound (A) having at least two coordination sites with a copper component.

The invention relates to alkenyl(perfluoroalkyl)phosphinic acids, to the preparation and intermediates thereof, to the use thereof as monomers for the preparation of oligomers and/or polymers, to the corresponding oligomers/polymers, to the corresponding support materials comprising the oligomers/polymers, and to the use thereof as ion exchangers, as catalysts or extraction medium and corresponding salts thereof.

Provided is a method for preparing L-glufosinate from an L-homoserine derivative compound, the method including a step (step a) of preparing a compound of Chemical Formula 2 from a compound of Chemical Formula 1, and a step (step b) of preparing a compound of Chemical Formula 3 from the compound of Chemical Formula 2.

The invention relates to a method for producing ethylenedialkylphosphinic acids, esters and salts, and to the use thereof as flame retardants. The claimed method is characterised in that •a) a phosphinic acid source (I) is reacted with olefins (IV) in the presence of catalyst A so as to obtain an alkylphosphonous acid, salt or ester (II) thereof, and •b) the alkylphosphonous acid, salt or ester (II) thereof obtained in this manner is reacted with acetylenic compound (V) in the presence of catalyst B in order to obtain the ethylenedialkylphosphinic acid derivative (III), •catalyst A being transition metals and/or transition metal compounds and/or catalyst systems composed of a transition metal and/or a transition metal compound and at least one ligand •and catalyst B being electromagnetic radiation.

##STR00001##

This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.